Financial Daily from THE HINDU group of publications
Thursday, Dec 04, 2003

News
Features
Stocks
Port Info
Archives

Group Sites

Corporate - Announcements
Industry & Economy - Health


Orchid diabetic drug to start human trials in Europe

Our Bureau

Chennai , Dec. 3

ORCHID Chemicals & Pharmaceuticals Ltd on Wednesday announced that an anti-diabetic drug developed by its associate company, Bexel Pharmaceuticals, would start clinical trials on humans in Europe on December 15.

The drug had received the European Independent Ethics Committee's approval to carry out Phase I clinical trials following successful pre-clinical trials on animals. In addition to combating diabetes, it also checks the user's tendency to gain weight.

According to a press release, Phase I trials are expected to end in April and once a part of Phase II trials are completed, the drug would be licensed to another company for further trials.

Indian companies typically license their new drugs to other companies for more sophisticated clinical trials overseas because of the large associated cost. Orchid's Managing Director, Mr K. Raghavendra Rao, had earlier told Business Line that Phase I trials were likely to cost about $1 million. Bexel Pharmaceuticals is a joint venture between Orchid and the US-based Bexel Biotech.

Article E-Mail :: Comment :: Syndication

Stories in this Section
IOC offers products to Bangladesh through Haldia


WHO pre-qualifies Ranbaxy's AIDS drug combination
Spl dividend from Colgate-Palmolive
Orchid diabetic drug to start human trials in Europe
Colgate-Palmolive changes director
Color Chips board meet
Cos can offer equity against all ECBs
Boston-based fund picks up stake in KEC
Maruti plans diesel engine plant
Asian Paints to set up new plant in TN
SRF board meet to on Dec 9 to consider nylon yarn proposal
Govt nod for unlisted cos' sweat equity to be mandatory
Haria Exports board meet on Jan 7
Super Spinning pins hope on new hybrid cotton
Balaji Tele pins hopes on new shows to improve financials
M&M auto sales up in Nov


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |

Copyright 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line